Overview
- 20 inspections across 20 sites are on record.
- 31 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-05-21.
At a glance
Inspections
20
Sites
20
Observations
31
Career since
Mar 2024
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| EMSL Analytical, Inc. DBA MPL Laboratories | 21 May 2026 | Human Drugs | View 483 → |
| Sciegen Pharmaceuticals Inc | 15 May 2026 | Human Drugs | View 483 → |
| Quagen Pharmaceuticals LLC | 17 Apr 2026 | Human Drugs | |
| Saptalis Pharmaceuticals LLC | 6 Mar 2026 | Human Drugs | View 483 → |
| Lonza Biologics, Inc. | 6 Feb 2026 | Human Drugs | On file |
Sites inspected
EMSL Analytical, Inc. DBA MPL LaboratoriesSparta, United States1 insp.
Sciegen Pharmaceuticals IncHauppauge, United States1 insp.
Quagen Pharmaceuticals LLCWest Caldwell, United States1 insp.
Saptalis Pharmaceuticals LLCHauppauge, United States1 insp.
Lonza Biologics, Inc.Portsmouth, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Jenny Sung3 shared
Anthony J Donato2 shared
Amatul H Marium2 shared
Mindy M Chou2 shared
Jessica S Estriplet2 shared
Daniel L Zheng1 shared
Alice S Tsao1 shared
Sean R Marcsisin1 shared
Lauren H Augustyniak1 shared
Tanya R Syffrard1 shared
Full investigator report
Get the verbatim findings behind Emmanuel T Donyina's 31 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site